Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

Shield MCD Test Can Detect Cancers Including Bladder, Colorectal, Esophageal

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

bloodtest

More from Clinical Trials

More from Policy & Regulation